Verastem (VSTM) Gross Margin (2018 - 2026)

Verastem's (VSTM) quarterly Gross Margin came in at 85.15% in Q1 2026, little changed quarter-over-quarter from 85.1% in Q4 2025.

Verastem (VSTM) Gross Margin (2018 - 2026) Analysis & Trends

Verastem's Gross Margin history runs 5 years deep, the most recent figure standing at 85.15% for Q1 2026.

On a quarterly basis, Gross Margin changed N/A year-over-year to 85.15% in Q1 2026; TTM through Mar 2026 was 85.13%, a N/A change from a year earlier, with the FY2025 full-year figure at 85.12%, changed N/A from the prior year.
Gross Margin steadied at 85.15% in Q1 2026 per VSTM's latest filing, from 85.1% in the prior quarter.
Across five years, Gross Margin topped out at 85.15% in Q1 2026 and bottomed at 85.1% in Q4 2025.

Peer Comparison

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Gross Margin (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-	-
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn	88.95%
4	NuCana	279.75 Bn	279.75 Bn	-	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn	86.85%
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn	91.79%
7	Belite Bio	62.51 Bn	62.51 Bn	-	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn	90.68%
9	Revolution Medicines	37.78 Bn	37.78 Bn	-	-
10	Verastem	166.09 Mn	-31.73 Mn	15.90 Mn	85.15%

Historic Data

Download Data

Date	Value
Mar 31, 2026	85.15%
Dec 31, 2025	85.10%
Sep 30, 2025	85.14%
Jun 30, 2025	85.12%
Dec 31, 2020	97.63%
Sep 30, 2020	98.90%
Jun 30, 2020	90.90%
Mar 31, 2020	90.21%
Dec 31, 2019	90.82%
Sep 30, 2019	95.89%
Jun 30, 2019	87.98%
Mar 31, 2019	90.54%
Dec 31, 2018	90.41%
Sep 30, 2018	99.68%